<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>将其添加为您在 Google 上的首选新闻来源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>医疗保健和生物技术股票在周一的盘后交易中出现显著波动，尽管新闻流有限，但多家公司仍录得强劲涨幅。</p>
<p>诺和诺德公司（Novo Nordisk A/S，NVO）在盘后交易中上涨 9.48%，至 52.66 美元，涨幅为 4.56 美元。这一涨势源于一个重要的监管里程碑，美国食品药品监督管理局（FDA）批准了诺和诺德的每日一次 Wegovy 药丸，这是美国首个用于肥胖的口服 GLP-1 药物。该药物适用于配合低热量饮食和增加体育活动，帮助肥胖成年人或因体重相关医疗状况而超重的人减重并维持效果。重要的是，Wegovy 还被批准用于降低肥胖或超重且已有心血管疾病的成年人发生重大不良心血管事件（包括死亡、心脏病发作或中风）的风险。</p>
<p>Neumora Therapeutics, Inc.（NMRA）在盘后交易中上涨 16.02%，至 2.10 美元，涨幅为 0.29 美元。尽管周一没有发布公司特定的新闻，但这一走势表明投资者的兴趣可能受到更广泛行业势头或投机交易的驱动。</p>
<p>BioRestorative Therapies, Inc.（BRTX）在盘后交易中上涨 6.90%，至 1.24 美元。尽管公司周一没有新的更新，投资者可能仍在对其 11 月 17 日宣布的 FDA 批准召开 Type B 会议以讨论其快速通道指定的 BRTX-100 项目的潜在加速生物制品许可申请（BLA）路径作出反应。该疗法正在开发用于慢性腰椎间盘疾病，会议定于 12 月中旬举行。</p>
<p>RenovoRx, Inc.（RNXT）在盘后交易中上涨 4.44%，收于 0.94 美元。公司周一没有新的公告，但本月早些时候披露其向美国临床肿瘤学会（ASCO）2026 年胃肠癌研讨会提交的摘要已被接受。RenovoRx 将在 1 月展示其正在进行的 III 期 TIGeR-PaC 试验的药代动力学和药效学子研究的结果。</p>
<p>IDEAYA Biosciences, Inc.（IDYA）在盘后交易中上涨 6.49%，至 37.81 美元。尽管周一没有发布新的更新，IDEAYA 最近宣布其 II/III 期 OptimUM-02 试验中已完全招募 435 名患者，该试验评估 darovasertib 与辉瑞的 crizotinib 联合用于转移性葡萄膜黑色素瘤。公司预计将在 2026 年第一季度报告无进展生存数据，这可能支持在美国的加速批准申请。</p>
<p>Healthcare Triangle, Inc.（HCTI）在盘后交易中上涨 6.72%，至 1.43 美元。公司周一没有新的消息，但在 12 月 10 日宣布与 Teyame AI LLC 达成了一项预先协议，作为其计划收购西班牙基于 AI 的客户体验公司 Teyame 360 SL 和 Datono Mediacion SL 的一部分。该交易预计将增强 Healthcare Triangle 在全球 AI 驱动的患者和客户参与解决方案中的地位。</p>
<p>Alphatec Holdings, Inc.（ATEC）在盘后交易中小幅上涨 2.80%，升至 21.28 美元。公司周一没有发布任何更新，但股票继续受益于投资者对脊柱手术技术提供商的信心。</p>
<p>如需评论和反馈，请联系：editorial@rttnews.com</p>
<p>商业新闻</p>

HCTI

诺和诺德公司

IDYA

<p>医疗和生物科技股票在盘后交易中大幅上涨，诺和诺德公司在其用于治疗肥胖的 Wegovy 药丸获得 FDA 批准后领涨。Neumora Therapeutics、BioRestorative Therapies、RenovoRx、Ideaya Biosciences、Healthcare Triangle 和 Alphatec Holdings 也因行业势头和近期公告而上涨。诺和诺德的药丸是美国首个获得批准的口服 GLP-1 肥胖药物，旨在降低心血管风险。其他公司则因投资者兴趣以及即将进行的试验或收购而受益</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>将其添加为您在 Google 上的首选新闻来源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Healthcare and biotechnology stocks saw notable moves in after-hours trading on Monday, with several companies posting strong gains despite limited news flow.</p>
<div class="lb-trans"><p>医疗保健和生物技术股票在周一的盘后交易中出现显著波动，尽管新闻流有限，但多家公司仍录得强劲涨幅。</p>
</div><p>Novo Nordisk A/S (NVO) surged in extended trading, climbing 9.48% to $52.66, up $4.56. The rally followed a major regulatory milestone as the U.S. Food and Drug Administration (FDA) approved Novo Nordisk's once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the United States. The pill is indicated for use alongside a reduced-calorie diet and increased physical activity to help adults with obesity, or those overweight with weight-related medical conditions, lose weight and maintain results. Importantly, Wegovy is also approved to reduce the risk of major adverse cardiovascular events, including death, heart attack, or stroke, in adults with obesity or overweight and established cardiovascular disease.</p>
<div class="lb-trans"><p>诺和诺德公司（Novo Nordisk A/S，NVO）在盘后交易中上涨 9.48%，至 52.66 美元，涨幅为 4.56 美元。这一涨势源于一个重要的监管里程碑，美国食品药品监督管理局（FDA）批准了诺和诺德的每日一次 Wegovy 药丸，这是美国首个用于肥胖的口服 GLP-1 药物。该药物适用于配合低热量饮食和增加体育活动，帮助肥胖成年人或因体重相关医疗状况而超重的人减重并维持效果。重要的是，Wegovy 还被批准用于降低肥胖或超重且已有心血管疾病的成年人发生重大不良心血管事件（包括死亡、心脏病发作或中风）的风险。</p>
</div><p>Neumora Therapeutics, Inc. (NMRA) advanced 16.02% after hours to $2.10, gaining $0.29. The move came despite no company-specific news being released on Monday, suggesting investor interest may be driven by broader sector momentum or speculative trading.</p>
<div class="lb-trans"><p>Neumora Therapeutics, Inc.（NMRA）在盘后交易中上涨 16.02%，至 2.10 美元，涨幅为 0.29 美元。尽管周一没有发布公司特定的新闻，但这一走势表明投资者的兴趣可能受到更广泛行业势头或投机交易的驱动。</p>
</div><p>BioRestorative Therapies, Inc. (BRTX) rose 6.90% to $1.24 in after-hours trading. While the company had no fresh updates on Monday, investors may still be reacting to its November 17 announcement that the FDA granted a Type B meeting to discuss a potential accelerated Biologics License Application (BLA) pathway for its Fast-Track-Designated BRTX-100 program. The therapy is being developed for chronic lumbar disc disease, with the meeting scheduled for mid-December.</p>
<div class="lb-trans"><p>BioRestorative Therapies, Inc.（BRTX）在盘后交易中上涨 6.90%，至 1.24 美元。尽管公司周一没有新的更新，投资者可能仍在对其 11 月 17 日宣布的 FDA 批准召开 Type B 会议以讨论其快速通道指定的 BRTX-100 项目的潜在加速生物制品许可申请（BLA）路径作出反应。该疗法正在开发用于慢性腰椎间盘疾病，会议定于 12 月中旬举行。</p>
</div><p>RenovoRx, Inc. (RNXT) added 4.44% to close at $0.94 after hours. The company had no new announcements on Monday, but earlier this month disclosed that its abstract submission to the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026 was accepted. RenovoRx will present findings from a pharmacokinetic and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC trial in January.</p>
<div class="lb-trans"><p>RenovoRx, Inc.（RNXT）在盘后交易中上涨 4.44%，收于 0.94 美元。公司周一没有新的公告，但本月早些时候披露其向美国临床肿瘤学会（ASCO）2026 年胃肠癌研讨会提交的摘要已被接受。RenovoRx 将在 1 月展示其正在进行的 III 期 TIGeR-PaC 试验的药代动力学和药效学子研究的结果。</p>
</div><p>IDEAYA Biosciences, Inc. (IDYA) gained 6.49% to $37.81 in extended trading. While no new updates were issued on Monday, IDEAYA recently announced full enrollment of 435 patients in its Phase 2/3 OptimUM-02 trial evaluating darovasertib in combination with Pfizer's crizotinib for metastatic uveal melanoma. The company expects to report progression-free survival data in the first quarter of 2026, which could potentially support an accelerated approval filing in the U.S.</p>
<div class="lb-trans"><p>IDEAYA Biosciences, Inc.（IDYA）在盘后交易中上涨 6.49%，至 37.81 美元。尽管周一没有发布新的更新，IDEAYA 最近宣布其 II/III 期 OptimUM-02 试验中已完全招募 435 名患者，该试验评估 darovasertib 与辉瑞的 crizotinib 联合用于转移性葡萄膜黑色素瘤。公司预计将在 2026 年第一季度报告无进展生存数据，这可能支持在美国的加速批准申请。</p>
</div><p>Healthcare Triangle, Inc. (HCTI) climbed 6.72% to $1.43 after hours. The company had no fresh news on Monday, but on December 10, it announced an Advance Agreement with Teyame AI LLC as part of its planned acquisition of Spain-based AI-powered customer experience firms Teyame 360 SL and Datono Mediacion SL. The deal is expected to strengthen Healthcare Triangle's position in global AI-driven patient and customer engagement solutions.</p>
<div class="lb-trans"><p>Healthcare Triangle, Inc.（HCTI）在盘后交易中上涨 6.72%，至 1.43 美元。公司周一没有新的消息，但在 12 月 10 日宣布与 Teyame AI LLC 达成了一项预先协议，作为其计划收购西班牙基于 AI 的客户体验公司 Teyame 360 SL 和 Datono Mediacion SL 的一部分。该交易预计将增强 Healthcare Triangle 在全球 AI 驱动的患者和客户参与解决方案中的地位。</p>
</div><p>Alphatec Holdings, Inc. (ATEC) posted a modest after-hours gain of 2.80%, rising to $21.28. The company did not issue any updates on Monday, but shares continued to benefit from investor confidence in the spine surgery technology provider.</p>
<div class="lb-trans"><p>Alphatec Holdings, Inc.（ATEC）在盘后交易中小幅上涨 2.80%，升至 21.28 美元。公司周一没有发布任何更新，但股票继续受益于投资者对脊柱手术技术提供商的信心。</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如需评论和反馈，请联系：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商业新闻</p>
</div>

生物科技股在盘后交易中表现亮眼：诺和诺德公司、Ideaya Biosciences 和 Healthcare Triangle 等公司股价上涨